{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:48:24Z","timestamp":1790938104693,"version":"4.1.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11523-025-01133-9","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T06:19:40Z","timestamp":1741069180000},"page":"217-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B\u00a0Cell Malignancies: A Narrative Review"],"prefix":"10.1007","volume":"20","author":[{"given":"David B.","family":"Miklos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2622-6513","authenticated-orcid":false,"given":"Alex","family":"Bokun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"issue":"5","key":"1133_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617\u201329.","journal-title":"Am J Hematol"},{"issue":"3","key":"1133_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316\u201327.","journal-title":"Am J Hematol"},{"issue":"5","key":"1133_CR3","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022\u2014a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638\u201356.","journal-title":"Am J Hematol"},{"issue":"11","key":"1133_CR4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918\u201332.","journal-title":"JAMA"},{"issue":"Suppl 2","key":"1133_CR5","first-page":"S11","volume":"97","author":"JA Woyach","year":"2022","unstructured":"Woyach JA. Management of relapsed\/refractory chronic lymphocytic leukemia. Am J Hematol. 2022;97(Suppl 2):S11\u20138.","journal-title":"Am J Hematol"},{"key":"1133_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.829983","volume":"12","author":"A Condoluci","year":"2022","unstructured":"Condoluci A, Rossi D. Biology and treatment of Richter transformation. Front Oncol. 2022;12: 829983.","journal-title":"Front Oncol"},{"issue":"5","key":"1133_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141(5):467\u201380.","journal-title":"Blood"},{"issue":"7","key":"1133_CR8","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.1002\/cam4.5551","volume":"12","author":"S Abbasi","year":"2023","unstructured":"Abbasi S, Totmaj MA, Abbasi M, et al. Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies. Cancer Med. 2023;12(7):7844\u201358.","journal-title":"Cancer Med"},{"key":"1133_CR9","unstructured":"IMBRUVICA (ibrutinib) [prescribing information]. South San Francisco: Pharmacyclics LLC; 2024."},{"issue":"21","key":"1133_CR10","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","volume":"6","author":"S Gill","year":"2022","unstructured":"Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774\u201385.","journal-title":"Blood Adv"},{"issue":"4","key":"1133_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","volume":"43","author":"JS Qin","year":"2020","unstructured":"Qin JS, Johnstone TG, Baturevych A, et al. Antitumor potency of an anti-CD19 chimeric antigen receptor t-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib. J Immunother. 2020;43(4):107\u201320.","journal-title":"J Immunother"},{"issue":"15","key":"1133_CR12","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","volume":"7","author":"M Mhibik","year":"2023","unstructured":"Mhibik M, Gaglione EM, Eik D, et al. Cytotoxicity of the CD3\u00d7CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Adv. 2023;7(15):4089\u2013101.","journal-title":"Blood Adv"},{"issue":"19","key":"1133_CR13","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1182\/blood.2020009686","volume":"138","author":"M Mhibik","year":"2021","unstructured":"Mhibik M, Gaglione EM, Eik D, et al. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL. Blood. 2021;138(19):1843\u201354.","journal-title":"Blood"},{"issue":"7","key":"1133_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jcyt.2023.03.005","volume":"25","author":"W Luo","year":"2023","unstructured":"Luo W, Li C, Wu J, et al. Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma. Cytotherapy. 2023;25(7):739\u201349.","journal-title":"Cytotherapy"},{"key":"1133_CR15","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1133_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/bjh.15918","volume":"186","author":"S Man","year":"2019","unstructured":"Man S, Henley P. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. Br J Haematol. 2019;186(2):220\u201333.","journal-title":"Br J Haematol"},{"issue":"9","key":"1133_CR17","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","volume":"121","author":"JC Riches","year":"2013","unstructured":"Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612\u201321.","journal-title":"Blood"},{"issue":"3","key":"1133_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3324\/haematol.2016.151100","volume":"102","author":"M Palma","year":"2017","unstructured":"Palma M, Gentilcore G, Heimersson K, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102(3):562\u201372.","journal-title":"Haematologica"},{"issue":"3","key":"1133_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","volume":"18","author":"C Nunes","year":"2012","unstructured":"Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C. Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res. 2012;18(3):678\u201387.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1133_CR20","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3324\/haematol.2012.077537","volume":"98","author":"D Brusa","year":"2013","unstructured":"Brusa D, Serra S, Coscia M, et al. The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98(6):953\u201363.","journal-title":"Haematologica"},{"issue":"8","key":"1133_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1465167","volume":"7","author":"M Wierz","year":"2018","unstructured":"Wierz M, Janji B, Berchem G, Moussay E, Paggetti J. High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia. Oncoimmunology. 2018;7(8): e1465167.","journal-title":"Oncoimmunology."},{"issue":"7","key":"1133_CR22","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1172\/JCI24176","volume":"115","author":"G G\u00f6rg\u00fcn","year":"2005","unstructured":"G\u00f6rg\u00fcn G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7):1797\u2013805.","journal-title":"J Clin Invest"},{"issue":"1","key":"1133_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.celrep.2016.02.084","volume":"15","author":"A Kabanova","year":"2016","unstructured":"Kabanova A, Sanseviero F, Candi V, et al. Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release. Cell Rep. 2016;15(1):9\u201318.","journal-title":"Cell Rep"},{"issue":"8","key":"1133_CR24","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","volume":"34","author":"PM Roessner","year":"2020","unstructured":"Roessner PM, Seiffert M. T cells in chronic lymphocytic leukemia: guardians or drivers of disease? Leukemia. 2020;34(8):2012\u201324.","journal-title":"Leukemia"},{"issue":"7","key":"1133_CR25","first-page":"2427","volume":"118","author":"AG Ramsay","year":"2008","unstructured":"Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427\u201337.","journal-title":"J Clin Invest"},{"issue":"14","key":"1133_CR26","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1182\/blood.2021013926","volume":"139","author":"N Purroy","year":"2022","unstructured":"Purroy N, Tong YE, Lemvigh CK, et al. Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood. 2022;139(14):2252\u20136.","journal-title":"Blood"},{"issue":"26","key":"1133_CR27","doi-asserted-by":"publisher","first-page":"40558","DOI":"10.18632\/oncotarget.9941","volume":"7","author":"J Wu","year":"2016","unstructured":"Wu J, Xu X, Lee EJ, et al. Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming. Oncotarget. 2016;7(26):40558\u201370.","journal-title":"Oncotarget"},{"issue":"3","key":"1133_CR28","first-page":"677","volume":"20","author":"K Giannopoulos","year":"2008","unstructured":"Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep. 2008;20(3):677\u201382.","journal-title":"Oncol Rep"},{"issue":"6","key":"1133_CR29","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","volume":"106","author":"M Beyer","year":"2005","unstructured":"Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106(6):2018\u201325.","journal-title":"Blood"},{"issue":"3","key":"1133_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.leukres.2010.08.010","volume":"35","author":"G D'Arena","year":"2011","unstructured":"D\u2019Arena G, Laurenti L, Minervini MM, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res. 2011;35(3):363\u20138.","journal-title":"Leuk Res"},{"issue":"2","key":"1133_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2249.2011.04466.x","volume":"166","author":"KP Piper","year":"2011","unstructured":"Piper KP, Karanth M, McLarnon A, et al. Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells. Clin Exp Immunol. 2011;166(2):154\u201363.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"1133_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/modpathol.2011.164","volume":"25","author":"A Biancotto","year":"2012","unstructured":"Biancotto A, Dagur PK, Fuchs JC, Wiestner A, Bagwell CB, McCoy JP Jr. Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia. Mod Pathol. 2012;25(2):246\u201359.","journal-title":"Mod Pathol"},{"issue":"10","key":"1133_CR33","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.leu.2403907","volume":"19","author":"M Motta","year":"2005","unstructured":"Motta M, Rassenti L, Shelvin BJ, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005;19(10):1788\u201393.","journal-title":"Leukemia"},{"key":"1133_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.intimp.2016.07.008","volume":"40","author":"N Pang","year":"2016","unstructured":"Pang N, Zhang R, Li J, et al. Increased IL-10\/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia. Int Immunopharmacol. 2016;40:57\u201364.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"1133_CR35","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/bloodadvances.2022008985","volume":"7","author":"W Gamal","year":"2023","unstructured":"Gamal W, Sahakian E, Pinilla-Ibarz J. The role of Th17 cells in chronic lymphocytic leukemia: friend or foe? Blood Adv. 2023;7(11):2401\u201317.","journal-title":"Blood Adv"},{"issue":"11","key":"1133_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078091","volume":"8","author":"I Hus","year":"2013","unstructured":"Hus I, Bojarska-Junak A, Chocholska S, et al. Th17\/IL-17A might play a protective role in chronic lymphocytic leukemia immunity. PLoS ONE. 2013;8(11): e78091.","journal-title":"PLoS ONE"},{"issue":"7","key":"1133_CR37","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100013R","volume":"35","author":"N Pang","year":"2021","unstructured":"Pang N, Alimu X, Chen R, et al. Activated galectin-9\/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia. FASEB J. 2021;35(7): e21556.","journal-title":"FASEB J"},{"issue":"3","key":"1133_CR38","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/ijms19030730","volume":"19","author":"GR Lee","year":"2018","unstructured":"Lee GR. The balance of Th17 versus Treg cells in autoimmunity. Int J Mol Sci. 2018;19(3):730.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1133_CR39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0145-2126(01)00194-1","volume":"26","author":"M Podhorecka","year":"2002","unstructured":"Podhorecka M, Dmoszynska A, Rolinski J, Wasik E. T type 1\/type 2 subsets balance in B-cell chronic lymphocytic leukemia\u2014the three-color flow cytometry analysis. Leuk Res. 2002;26(7):657\u201360.","journal-title":"Leuk Res"},{"issue":"1","key":"1133_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13046-021-02115-1","volume":"40","author":"C Moreno","year":"2021","unstructured":"Moreno C, Mu\u00f1oz C, Terol MJ, Hern\u00e1ndez-Rivas J, Villanueva M. Restoration of the immune function as a complementary strategy to treat chronic lymphocytic leukemia effectively. J Exp Clin Cancer Res. 2021;40(1):321.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1133_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1158\/1078-0432.CCR-14-3017","volume":"22","author":"A Vardi","year":"2016","unstructured":"Vardi A, Agathangelidis A, Stalika E, et al. Antigen selection shapes the T-cell repertoire in chronic lymphocytic leukemia. Clin Cancer Res. 2016;22(1):167\u201374.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1133_CR42","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","volume":"198","author":"Q Yin","year":"2017","unstructured":"Yin Q, Sivina M, Robins H, et al. Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia. J Immunol. 2017;198(4):1740\u20137.","journal-title":"J Immunol"},{"issue":"16","key":"1133_CR43","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1158\/1078-0432.CCR-20-4894","volume":"27","author":"MJ Baptista","year":"2021","unstructured":"Baptista MJ, Baskar S, Gaglione EM, et al. Select antitumor cytotoxic CD8(+) T clonotypes expand in patients with chronic lymphocytic leukemia treated with ibrutinib. Clin Cancer Res. 2021;27(16):4624\u201333.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1133_CR44","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1182\/blood-2002-03-0746","volume":"101","author":"MR Rezvany","year":"2003","unstructured":"Rezvany MR, Jeddi-Tehrani M, Wigzell H, Osterborg A, Mellstedt H. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood. 2003;101(3):1063\u2013701070.","journal-title":"Blood"},{"issue":"9","key":"1133_CR45","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/leu.2011.111","volume":"25","author":"JP Hofbauer","year":"2011","unstructured":"Hofbauer JP, Heyder C, Denk U, et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia. 2011;25(9):1452\u20138.","journal-title":"Leukemia"},{"issue":"7","key":"1133_CR46","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/leu.2016.362","volume":"31","author":"A Vardi","year":"2017","unstructured":"Vardi A, Vlachonikola E, Karypidou M, et al. Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements. Leukemia. 2017;31(7):1555\u201361.","journal-title":"Leukemia"},{"issue":"6","key":"1133_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1432328","volume":"7","author":"G Blanco","year":"2018","unstructured":"Blanco G, Vardi A, Puiggros A, et al. Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. Oncoimmunology. 2018;7(6): e1432328.","journal-title":"Oncoimmunology."},{"issue":"18","key":"1133_CR48","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1158\/1078-0432.CCR-19-3827","volume":"26","author":"A Vardi","year":"2020","unstructured":"Vardi A, Vlachonikola E, Papazoglou D, et al. T-Cell dynamics in chronic lymphocytic leukemia under different treatment modalities. Clin Cancer Res. 2020;26(18):4958\u201369.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1133_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41408-021-00477-5","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Sinha S, Wellik LE, et al. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer J. 2021;11(5):86.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1133_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43\u201356.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1133_CR51","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, et al. Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353\u201363.","journal-title":"Am J Hematol"},{"issue":"11","key":"1133_CR52","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440\u201350.","journal-title":"Blood Adv"},{"issue":"3","key":"1133_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787\u201398.","journal-title":"Leukemia"},{"issue":"5","key":"1133_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.74","volume":"8","author":"P Ghia","year":"2024","unstructured":"Ghia P, Owen C, Allan JN, et al. First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: a pooled post hoc analysis. HemaSphere. 2024;8(5): e74.","journal-title":"HemaSphere."},{"key":"1133_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.727531","volume":"9","author":"S Zhu","year":"2021","unstructured":"Zhu S, Gokhale S, Jung J, et al. Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets - beyond B lymphocytes. Front Cell Dev Biol. 2021;9: 727531.","journal-title":"Front Cell Dev Biol."},{"issue":"10","key":"1133_CR56","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41423-019-0270-9","volume":"17","author":"S Xia","year":"2020","unstructured":"Xia S, Liu X, Cao X, Xu S. T-cell expression of Bruton\u2019s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Cell Mol Immunol. 2020;17(10):1042\u201352.","journal-title":"Cell Mol Immunol"},{"issue":"15","key":"1133_CR57","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539\u201349.","journal-title":"Blood"},{"issue":"21","key":"1133_CR58","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1182\/blood-2017-12-822569","volume":"132","author":"I de Weerdt","year":"2018","unstructured":"de Weerdt I, Hofland T, Lameris R, et al. Improving CLL V\u03b39V\u03b42-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib. Blood. 2018;132(21):2260\u2013672.","journal-title":"Blood"},{"issue":"8","key":"1133_CR59","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127(8):3052\u201364.","journal-title":"J Clin Invest"},{"issue":"8","key":"1133_CR60","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","volume":"76","author":"A Stiff","year":"2016","unstructured":"Stiff A, Trikha P, Wesolowski R, et al. Myeloid-derived suppressor cells express Bruton\u2019s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Res. 2016;76(8):2125\u201336.","journal-title":"Cancer Res"},{"issue":"suppl 6","key":"1133_CR61","doi-asserted-by":"publisher","first-page":"Abstract 57","DOI":"10.1158\/1538-7445.AM2024-57","volume":"84","author":"BF Frost","year":"2024","unstructured":"Frost BF, Shestova O, Shen F, Sharpe C, Byrd JC, Gill SI. Ibrutinib improves chimeric antigen receptor T cell control of leukemia by inhibiting myeloid-derived suppressor cells. Cancer Res. 2024;84(suppl 6):Abstract 57.","journal-title":"Cancer Res"},{"key":"1133_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106432","volume":"97","author":"IG Solman","year":"2020","unstructured":"Solman IG, Blum LK, Hoh HY, et al. Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia. Leuk Res. 2020;97: 106432.","journal-title":"Leuk Res"},{"key":"1133_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106520","volume":"102","author":"IG Solman","year":"2021","unstructured":"Solman IG, Blum LK, Burger JA, et al. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021;102: 106520.","journal-title":"Leuk Res"},{"key":"1133_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637186","volume":"11","author":"MC Puzzolo","year":"2021","unstructured":"Puzzolo MC, Del Giudice I, Peragine N, et al. TH2\/TH1 shift under ibrutinib treatment in chronic lymphocytic leukemia. Front Oncol. 2021;11: 637186.","journal-title":"Front Oncol"},{"issue":"25","key":"1133_CR65","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1182\/blood-2016-06-715284","volume":"128","author":"CE Ryan","year":"2016","unstructured":"Ryan CE, Sahaf B, Logan AC, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016;128(25):2899\u2013908.","journal-title":"Blood"},{"issue":"1","key":"1133_CR66","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","volume":"19","author":"JE Davis","year":"2021","unstructured":"Davis JE, Sharpe C, Mason K, Tam CS, Koldej RM, Ritchie DS. Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence. J Transl Med. 2021;19(1):473.","journal-title":"J Transl Med"},{"issue":"7","key":"1133_CR67","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","volume":"22","author":"CU Niemann","year":"2016","unstructured":"Niemann CU, Herman SE, Maric I, et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib\u2014findings from an investigator-initiated phase ii study. Clin Cancer Res. 2016;22(7):1572\u201382.","journal-title":"Clin Cancer Res"},{"key":"1133_CR68","doi-asserted-by":"publisher","first-page":"1201415","DOI":"10.3389\/fimmu.2023.1201415","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Zhao M, Kiernan CH, et al. Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK. Front Immunol. 2023;14:1201415.","journal-title":"Front Immunol"},{"issue":"1","key":"1133_CR69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/blood.2023020554","volume":"143","author":"D Papazoglou","year":"2024","unstructured":"Papazoglou D, Wang XV, Shanafelt TD, et al. Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial. Blood. 2024;143(1):57\u201363.","journal-title":"Blood"},{"issue":"1","key":"1133_CR70","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41467-019-14081-6","volume":"11","author":"AF Rendeiro","year":"2020","unstructured":"Rendeiro AF, Krausgruber T, Fortelny N, et al. Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. Nat Commun. 2020;11(1):577.","journal-title":"Nat Commun"},{"key":"1133_CR71","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1182\/blood-2023-186604","volume":"142","author":"S Thangavadivel","year":"2023","unstructured":"Thangavadivel S, Misra S, Benrashid S, et al. Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with Ibrutinib. Blood. 2023;142:3262.","journal-title":"Blood"},{"issue":"4","key":"1133_CR72","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10875-019-00632-5","volume":"39","author":"A Eken","year":"2019","unstructured":"Eken A, Cansever M, Somekh I, et al. Genetic deficiency and biochemical inhibition of ITK affect human Th17, treg, and innate lymphoid cells. J Clin Immunol. 2019;39(4):391\u2013400.","journal-title":"J Clin Immunol"},{"key":"1133_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9: 630942.","journal-title":"Front Cell Dev Biol."},{"issue":"1","key":"1133_CR74","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/ijms21010068","volume":"21","author":"M Mhibik","year":"2019","unstructured":"Mhibik M, Wiestner A, Sun C. Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL. Int J Mol Sci. 2019;21(1):68.","journal-title":"Int J Mol Sci"},{"issue":"26","key":"1133_CR75","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle CJ, Hay KA, Hanafi LA, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified t cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010\u201320.","journal-title":"J Clin Oncol"},{"issue":"303","key":"1133_CR76","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.","journal-title":"Sci Transl Med."},{"issue":"5","key":"1133_CR77","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey NV, Shaw PA, Hexner EO, et al. Optimizing chimeric antigen receptor T-Cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 2020;38(5):415\u201322.","journal-title":"J Clin Oncol"},{"key":"1133_CR78","unstructured":"Bristol Myers Squibb. U.S. FDA approves Bristol Myers Squibb\u2019s Breyanzi \u00ae as the first and only CAR T cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [press release]. March 14, 2024. Available from: https:\/\/news.bms.com\/news\/details\/2024\/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Breyanzi--as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-CLL-or-Small-Lymphocytic-Lymphoma-SLL\/default.aspx. Accessed 7 Aug 2024."},{"issue":"10402","key":"1133_CR79","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study. Lancet. 2023;402(10402):641\u201354.","journal-title":"Lancet"},{"key":"1133_CR80","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. Updated May, 15, 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma. Accessed 7 Aug 2024."},{"issue":"1","key":"1133_CR81","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ejh.14076","volume":"112","author":"AN Khan","year":"2024","unstructured":"Khan AN, Asija S, Pendhari J, Purwar R. CAR-T cell therapy in hematological malignancies: where are we now and where are we heading for? Eur J Haematol. 2024;112(1):6\u201318.","journal-title":"Eur J Haematol"},{"key":"1133_CR82","unstructured":"US Food & Drug Administration. FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma. Updated May 30, 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma. Accessed 7 Aug 2024."},{"issue":"3","key":"1133_CR83","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555\u201367.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1133_CR84","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.23.02214","volume":"42","author":"M Wang","year":"2024","unstructured":"Wang M, Siddiqi T, Gordon LI, et al. Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024;42(10):1146\u201357.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1133_CR85","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"19","key":"1133_CR86","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307\u201315.","journal-title":"Blood"},{"issue":"10","key":"1133_CR87","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1133_CR88","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024;143(5):404\u201316.","journal-title":"Blood"},{"issue":"4","key":"1133_CR89","first-page":"170","volume":"21","author":"F Lutfi","year":"2023","unstructured":"Lutfi F, Patel A, Mehta J, Goyal A, Dahiya S. Second-line treatment with CAR T-cell therapy for large B-cell lymphoma. Clin Adv Hematol Oncol. 2023;21(4):170\u20138.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"17","key":"1133_CR90","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2023021567","volume":"143","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Fowler NH, Dickinson M, et al. Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update. Blood. 2024;143(17):1713\u201325.","journal-title":"Blood"},{"issue":"8","key":"1133_CR91","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study [published correction appears in Nat Med. 2024;30(8):2374]. Nat Med. 2024;30(8):2199\u2013207.","journal-title":"Nat Med"},{"issue":"6","key":"1133_CR92","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496\u2013506.","journal-title":"Blood"},{"issue":"4","key":"1133_CR93","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"26","key":"1133_CR94","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"},{"issue":"12","key":"1133_CR95","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000988","volume":"7","author":"C Vitale","year":"2023","unstructured":"Vitale C, Griggio V, Perutelli F, Coscia M. CAR-modified cellular therapies in chronic lymphocytic leukemia: is the uphill road getting less steep? HemaSphere. 2023;7(12): e988.","journal-title":"HemaSphere."},{"issue":"13","key":"1133_CR96","first-page":"1832","volume":"137","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Dahiya S, Jain MD, et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021;137(13):1832\u20135.","journal-title":"Blood"},{"issue":"6","key":"1133_CR97","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1133_CR98","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","volume":"132","author":"HR Robinson","year":"2018","unstructured":"Robinson HR, Qi J, Cook EM, et al. A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Blood. 2018;132(5):521\u201332.","journal-title":"Blood"},{"key":"1133_CR99","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1182\/blood-2019-128564","volume":"134","author":"K Patel","year":"2019","unstructured":"Patel K, Michot J-M, Chanan-Khan AA, et al. Preliminary safety and anti-tumor activity of XmAb13676, an Anti-CD20 x Anti-CD3 bispecific antibody, in patients with relapsed\/refractory non-hodgkin\u2019s lymphoma and chronic lymphocytic leukemia. Blood. 2019;134:4079.","journal-title":"Blood"},{"issue":"5","key":"1133_CR100","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.21.00931","volume":"40","author":"LE Budde","year":"2022","unstructured":"Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-Cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40(5):481\u201391.","journal-title":"J Clin Oncol"},{"key":"1133_CR101","unstructured":"European Medicines Agency. Lunsumio 1 mg concentrate for solution for infusion (SPC) Lunsumio 30 mg concentrate for solution for infusion (SPC). London, UK: European Medicines Agency; 2024. Updated 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lunsumio-epar-product-information_en.pdf."},{"key":"1133_CR102","unstructured":"LUNSUMIO\u2122 (mosunetuzumab-axgb) injection, for intravenous use [prescribing information]. 2022. South San Francisco: Genentech Inc; 2022. https:\/\/www.gene.com\/download\/pdf\/lunsumio_prescribing.pdf."},{"key":"1133_CR103","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphomalar-lymphoma. Updated February 23, 2022. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma."},{"issue":"24","key":"1133_CR104","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220\u201331.","journal-title":"N Engl J Med"},{"key":"1133_CR105","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas. Updated June 16, 2023. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell."},{"issue":"18","key":"1133_CR106","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory b-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959\u201370.","journal-title":"J Clin Oncol"},{"key":"1133_CR107","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2021-148949","volume":"138","author":"T Phillips","year":"2021","unstructured":"Phillips T, Dickinson M, Morschhauser F, et al. Glofitamab step-up dosing induces high response rates in patients (pts) with relapsed or refractory (R\/R) mantle cell lymphoma (MCL), most of whom had failed prior Bruton\u2019s tyrosine kinase inhibitor (BTKi) therapy. Blood. 2021;138:130.","journal-title":"Blood"},{"issue":"16_suppl","key":"1133_CR108","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1200\/JCO.2024.42.16_suppl.7008","volume":"42","author":"TJ Phillips","year":"2024","unstructured":"Phillips TJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab monotherapy in patients with heavily pretreated relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): updated analysis from a phase I\/II study. J Clin Oncol. 2024;42(16_suppl):7008.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1133_CR109","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41(12):2238\u201347.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1133_CR110","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1200\/JCO.2024.42.16_suppl.7015","volume":"42","author":"J Vose","year":"2024","unstructured":"Vose J, Vitolo U, Lugtenburg P, et al. EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: expanding the clinical utility of epcoritamab in relapsed or refractory (R\/R) FL. J Clin Oncol. 2024;42(16_suppl):7015.","journal-title":"J Clin Oncol"},{"key":"1133_CR111","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma. Updated June 26, 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma."},{"key":"1133_CR112","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma. Updated May 19, 2023. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell."},{"issue":"10","key":"1133_CR113","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","volume":"34","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34(10):1104\u201311.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1133_CR114","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","volume":"9","author":"R Bannerji","year":"2022","unstructured":"Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327\u201339.","journal-title":"Lancet Haematol."},{"issue":"2","key":"1133_CR115","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.seminhematol.2024.01.001","volume":"61","author":"A Borogovac","year":"2024","unstructured":"Borogovac A, Siddiqi T. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies. Semin Hematol. 2024;61(2):119\u201330.","journal-title":"Semin Hematol"},{"issue":"9","key":"1133_CR116","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.2023022348","volume":"143","author":"SJ Schuster","year":"2024","unstructured":"Schuster SJ, Huw LY, Bolen CR, et al. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas. Blood. 2024;143(9):822\u201332.","journal-title":"Blood"},{"issue":"suppl 1","key":"1133_CR117","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2023-181805","volume":"142","author":"V Plaks","year":"2023","unstructured":"Plaks V, Cyril V, Riedell PA, et al. Combination of Ibrutinib with CD19 chimeric antigen receptor (CAR) T cells suggests greater contribution to CAR T-cell efficacy than other approved BTK inhibitors in the preclinical setting. Blood. 2023;142(suppl 1):2817.","journal-title":"Blood"},{"issue":"2","key":"1133_CR118","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ijc.33212","volume":"148","author":"F Fan","year":"2021","unstructured":"Fan F, Yoo HJ, Stock S, et al. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. Int J Cancer. 2021;148(2):419\u201328.","journal-title":"Int J Cancer"},{"issue":"9","key":"1133_CR119","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117\u201327.","journal-title":"Blood"},{"issue":"9","key":"1133_CR120","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122627","volume":"5","author":"MB Geyer","year":"2019","unstructured":"Geyer MB, Riviere I, Senechal B, et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL. JCI Insight. 2019;5(9): e122627.","journal-title":"JCI Insight."},{"issue":"7","key":"1133_CR121","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/cas.14915","volume":"112","author":"M Liu","year":"2021","unstructured":"Liu M, Deng H, Mu J, et al. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. Cancer Sci. 2021;112(7):2642\u201351.","journal-title":"Cancer Sci"},{"issue":"11","key":"1133_CR122","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","volume":"22","author":"M Ruella","year":"2016","unstructured":"Ruella M, Kenderian SS, Shestova O, et al. The Addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016;22(11):2684\u201396.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1133_CR123","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/leu.2016.262","volume":"31","author":"M Ruella","year":"2017","unstructured":"Ruella M, Kenderian SS, Shestova O, et al. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia. 2017;31(1):246\u20138.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"1133_CR124","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-140622","volume":"136","author":"WG Wierda","year":"2020","unstructured":"Wierda WG, Dorritie KA, Munoz J, et al. Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Blood. 2020;136(Suppl 1):39\u201340.","journal-title":"Blood"},{"key":"1133_CR125","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2020-134270","volume":"136","author":"JC Chavez","year":"2020","unstructured":"Chavez JC, Locke FL, Napier E, et al. Ibrutinib before apheresis may improve tisagenlecleucel manufacturing in relapsed\/refractory adult diffuse large B-cell lymphoma: initial results from a phase 1b study. Blood. 2020;136:3\u20134.","journal-title":"Blood"},{"issue":"8","key":"1133_CR126","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023021306","volume":"143","author":"A Minson","year":"2024","unstructured":"Minson A, Hamad N, Cheah CY, et al. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood. 2024;143(8):673\u201384.","journal-title":"Blood"},{"issue":"19","key":"1133_CR127","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650\u201360.","journal-title":"Blood"},{"issue":"22","key":"1133_CR128","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1182\/bloodadvances.2023011399","volume":"7","author":"EC Liang","year":"2023","unstructured":"Liang EC, Albittar A, Huang JJ, et al. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed\/refractory CLL. Blood Adv. 2023;7(22):6990\u20137005.","journal-title":"Blood Adv"},{"issue":"2","key":"1133_CR129","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bjh.15911","volume":"186","author":"SH Gohil","year":"2019","unstructured":"Gohil SH, Evans R, Harasser M, et al. Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol. 2019;186(2):380\u20132.","journal-title":"Br J Haematol"},{"issue":"20","key":"1133_CR130","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1158\/1078-0432.CCR-22-0504","volume":"28","author":"PM Barr","year":"2022","unstructured":"Barr PM, Tedeschi A, Wierda WG, et al. Effective tumor debulking with ibrutinib before initiation of venetoclax: results from the CAPTIVATE minimal residual disease and fixed-duration cohorts. Clin Cancer Res. 2022;28(20):4385\u201391.","journal-title":"Clin Cancer Res"},{"key":"1133_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.706087","volume":"11","author":"C Lyu","year":"2021","unstructured":"Lyu C, Cui R, Wang J, et al. Intensive debulking chemotherapy improves the short-term and long-term efficacy of anti-CD19-CAR-T in refractory\/relapsed DLBCL with high tumor bulk. Front Oncol. 2021;11: 706087.","journal-title":"Front Oncol"},{"issue":"9","key":"1133_CR132","doi-asserted-by":"publisher","first-page":"E966","DOI":"10.1073\/pnas.1500712112","volume":"112","author":"I Sagiv-Barfi","year":"2015","unstructured":"Sagiv-Barfi I, Kohrt HEK, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci USA. 2015;112(9):E966\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"1133_CR133","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","volume":"7","author":"N Jain","year":"2023","unstructured":"Jain N, Senapati J, Thakral B, et al. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023;7(10):1958\u201366.","journal-title":"Blood Adv"},{"issue":"1","key":"1133_CR134","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-023-01496-4","volume":"16","author":"N Jain","year":"2023","unstructured":"Jain N, Mamgain M, Chowdhury SM, et al. Beyond Bruton\u2019s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents. J Hematol Oncol. 2023;16(1):99.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1133_CR135","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study. Lancet Haematol. 2019;6(2):e67\u201378.","journal-title":"Lancet Haematol."},{"issue":"16_suppl","key":"1133_CR136","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.1200\/JCO.2023.41.16_suppl.7538","volume":"41","author":"DM Stephens","year":"2023","unstructured":"Stephens DM, Brown JR, Ma S, et al. Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: pooled analysis of 10 clinical trials. J Clin Oncol. 2023;41(16_suppl):7538\u20137538.","journal-title":"J Clin Oncol"},{"key":"1133_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020507","author":"JA Woyach","year":"2023","unstructured":"Woyach JA, Barr PM, Kipps TJ, et al. Characteristics and clinical outcomes of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma receiving ibrutinib for \u22655 years in the RESONATE-2 study. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15020507.","journal-title":"Cancers (Basel)."},{"issue":"14","key":"1133_CR138","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01133-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01133-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01133-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T03:39:16Z","timestamp":1743305956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01133-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":138,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1133"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01133-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"10 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial support was provided by Janssen Scientific Affairs, LLC, a Johnson & Johnson company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DBM reports consulting\/advisory roles for Adaptive Biotechnologies, Adicet, AlloGene, Janssen, Juno-Celgene-BMS, Kite-Gilead, Miltenyi Biotech, Novartis, Pharmacyclics LLC, an AbbVie Company, Precision Bioscience, and Takeda; and reports research funding from 2seventy bio, Adaptive Biotechnologies, Adicet Bio, AlloGene, Pharmacyclics LLC, an AbbVie Company, Genentech, Kite-Gilead, Miltenyi Biotech, Novartis, and Roche. PAR reports consulting\/advisory roles for AbbVie, ADC Therapeutics, BeiGene, BMS, CVS Caremark, Genmab, Intellia Therapeutics, Janssen, Kite-Gilead, Nektar Therapeutics, Novartis, Nurix Therapeutics, Pharmacyclics LLC, an AbbVie Company, and Sana Biotechnology; and reports research funding from BMS, Calibr, CRISPR Therapeutics, Fate Therapeutics, Kite-Gilead, MorphoSys, Nkarta, Novartis, Roche, Tessa Therapeutics, and Xencor. AB reports employment and stock ownership at Janssen. JCC reports consulting roles for AstraZeneca, BeiGene, BMS, GenMab, Kite-Gilead, and Novartis; reports research funding from AstraZeneca, Janssen, and Kite-Gilead; and reports receiving honoraria from AstraZeneca, BeiGene, Janssen, and Lilly. SJS reports consulting\/advisory roles for AbbVie, AstraZeneca, BeiGene, BioNTech, Caribou Biosciences, Genmab, Kite-Gilead, Legend Biotech, Novartis, and viTToria Biotherapeutics; and reports receiving honoraria from Janssen and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"No new data were generated or analyzed in support of this research.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed equally to manuscript conceptualization, writing, editing, and reviewing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}